Key points
- ARK Investment Management (Cathie Wood) now owns 5.33% of GeneDx (WGS), an SEC filing dated August 7 shows.
- The stake has more than tripled since September, from 446,979 shares to 1,581,810.
- GeneDx shares are up more than 9% Friday after beating Q2 earnings estimates and reaffirming full-year guidance.
ARK Investment Management filed an amended Schedule 13G on GeneDx Holdings Corp. (WGS) this week. It puts Cathie Wood's firm at 5.33 percent of the company, 1,581,810 shares as of July 31, crossing the five percent line that triggers this kind of disclosure in the first place. The more interesting part is how ARK got there.
This is ARK's second notable SEC disclosure this week, after the fund also bought nearly $20 million of SpaceX as that stock sold off Wednesday.
Every quarterly filing since last September shows the same thing. The count has climbed every quarter for the better part of a year.
| Filing period | GeneDx shares held |
|---|---|
| Sept. 30, 2025 (13F) | 446,979 |
| Dec. 31, 2025 (13F) | 604,561 |
| March 31, 2026 (13F) | 1,324,583 |
| July 31, 2026 (13G/A) | 1,581,810 |
ARK's position more than tripled in ten months, and the biggest single jump landed in the worst quarter. Between January and March, GeneDx fell from about $130 to about $64. In that same stretch the stake went from 604,561 shares to 1,324,583. At Friday's price, the full position is worth about $121 million.
This is the passive version of the disclosure, the kind funds file when they're simply holding a stake. Board seats and proxy fights come with the more assertive version, a Schedule 13D. We've broken down the difference between the two filings before.
GeneDx has had a genuinely wild year by any measure. The stock hit a 52-week high of $170.87 in early December, then fell to $32.21 by early May, an 81 percent drop in five months. It's more than doubled since, helped along by the company's Q2 revenue beat on August 3: $114.4 million against $112.1 million expected, with exome and genome test volume up 32 percent to 30,785. CEO Katherine Stueland called it a quarter where the company "successfully navigated our return to profitability." Analysts have been raising price targets since. Canaccord Genuity took its target to $90 from $75 this week. Shares were trading around $76 Friday afternoon, up more than 9 percent on the day, separate from ARK's filing.
None of this proves ARK called the bottom, or that Wood's reasoning matches anyone else's. A 13G shows what a fund owns and when it crossed a reporting threshold. The reasoning stays private. What the filings do show is a position that grew every single quarter for ten months, through an 81 percent crash and a climb back that's more than doubled the stock since. Track GeneDx's own SEC filings here, and read what the data actually says about copying a move like this one.
Cover photo: Cathie Wood, ARK CEO. Photo by Caroline Wood / Wikimedia Commons, CC BY-SA 4.0, cropped.
This isn't a recommendation to buy or sell GeneDx, or anything else here. Do your own research, and check with a licensed financial professional before you act on any of it.
Sources
- ARK Investment Management LLC, amended Schedule 13G on GeneDx Holdings Corp., filed with the SEC August 7, 2026.
- ARK Investment Management LLC, Form 13F-HR quarterly holdings for periods ended September 30, 2025, December 31, 2025 and March 31, 2026.
- GeneDx Holdings Corp., second quarter 2026 earnings release, filed with the SEC August 3, 2026.
- Live market data via Robinhood, August 7, 2026.
